Sign In
Buy IMMP
$0.407
-0.0093 (-2.24%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - March 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of I
IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm
08:00pm, Friday, 20'th Mar 2026
LOS ANGELES--(BUSINESS WIRE)---- $IMMP--IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm.
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Immutep Ltd.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
10:00am, Thursday, 19'th Mar 2026
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advised to co
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
08:00am, Thursday, 19'th Mar 2026
Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR confer
Immutep Reported TACTI-004 Futility Analysis Was "On Track" in January 2026 -- Weeks Later the Trial Was Halted After Failing to Meet Efficacy Endpoints NEW YORK, March 18, 2026 /PRNewswire/ -- Shareh
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
03:02pm, Wednesday, 18'th Mar 2026
NEW YORK, March 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Immutep Lt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
06:14pm, Tuesday, 17'th Mar 2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited (“Immutep” or the “Company”) (NASDAQ: IMMP). Such investors are a
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP
03:15pm, Tuesday, 17'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMM
Ongoing Investigation into Immutep Limited (IMMP): Contact Levi & Korsinsky About Potential Fraud
11:46am, Tuesday, 17'th Mar 2026
New York, New York--(Newsfile Corp. - March 17, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited ("Immutep Limited") (NASDAQ: IMMP) concerning po
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Immutep Limited (NASDAQ: IMMP). The investigation focuses on Immutep exec
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
08:00am, Friday, 13'th Mar 2026
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ:
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
08:00am, Friday, 06'th Feb 2026
SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune d
Immutep Quarterly Activities Report Q2 FY26
08:00am, Thursday, 29'th Jan 2026
Media Release Entered into strategic collaboration with Dr. Reddy's for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater China In January
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely
12:59pm, Monday, 22'nd Dec 2025
Immutep shares update on Phase I study of LAG-3 agonist antibody for autoimmune diseases, showing positive safety and efficacy data.
